Argenta Announces Record Year for Peer-Reviewed Publications
Argenta, a Galapagos NV, a company that provides drug discovery services from target validation to proof of concept, has announced that 2013 has seen a record number of peer-reviewed publications featuring its scientists as co-authors with its clients and collaborators.
The 2013 total of 15 publications surpasses the previous record of 13 achieved in 2007. The publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept and include papers in such prestigious journals as Nature and Proceedings of the National Academy of the USA. Details of these, and other Argenta publications, can be found on the company’s website.
Dr John Montana, Managing Director of Argenta, commented: “Argenta stands or falls by the quality of the science that it conducts for and together with its clients. This record number of publications in high-quality, peer-reviewed scientific journals is another indication of the scientific prowess of Argenta’s industry-experienced staff and the success that we have achieved in partnership with our clients.”
A further indication of Argenta’s strength in drug discovery is the 40 development compounds that it has delivered on behalf of its clients during the 13 years since its inception. The clinical progress of some of these can be seen on the company’s website.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance